平安好醫生(01833.HK)攜手國醫大師李佃貴推動中醫發展
平安好醫生(01833.HK)與國醫大師李佃貴教授及其弟子共同舉辦學術研討會及培訓會,向近300名平安健康自有中醫科醫療團隊的醫生提供培訓,分享中西醫分別對慢性萎縮性胃炎的研究及治療方法,傳授濁毒理論治療慢性萎縮性胃炎的經驗。
此前,李佃貴教授已在平安健康APP成立國醫特聘工作室,為用戶提供在線中醫問診服務。未來其數十名弟子也將加入平安健康APP名醫工作室。
平安好醫生主席兼行政總裁方蔚豪表示,希望能與更多像李佃貴這樣的國醫大師合作交流,傳承和發揚更多中醫治療方式和手段,讓優質中醫資源能下沉到偏遠地區的同時,也為中醫走向世界獻出一份力量。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.